Eversight Teams Up with LighTopTech to Improve Imaging Modalities for Eye Tissues
Eversight has partnered up with LighTopTech to elevate the standards of imaging modalities for eye tissues. This ambitious partnership, spanning over four years, sets out to redefine the landscape of ocular imaging in both clinical and research domains.
LighTopTech's OCX System
The cornerstone of this collaboration is the integration of LighTopTech's cutting-edge dual modality OCX system into Eversight's research and development initiatives. This innovative system seamlessly combines optical coherence tomography (OCT) with optical coherence microscopy (OCM), offering a comprehensive solution for detailed corneal tissue analysis.
Dr. Onkar B. Sawant, Vice President of Research & Development at Eversight, expressed confidence in the potential of the OCX system to revolutionize ocular imaging technology. "The OCX system represents a significant advancement in ocular imaging technology, and we are confident in its potential to improve clinical precision and support vision research," Dr. Sawant stated in a company news release.
Integration within Eye Bank Operations
Central to the collaboration is the utilization of the OCX imaging system to enhance corneal tissue evaluations within Eversight's eye bank operations. This integration aims to ensure that tissue processing meets the exacting standards of surgeons for various cornea surgeries while also detecting anomalies that may render the tissue unsuitable for transplantation.
Furthermore, Eversight will provide crucial data to LighTopTech to inform the development of OCX software. This software holds the promise of automating critical tasks such as endothelial cell counting, a pivotal metric for eye banks, alongside other essential eye tissue measurements.
The partnership, further fortified by a grant from the Michigan Foundation for Vision Awareness, underscores the commitment to innovation and advancement in ocular imaging. This funding plays a pivotal role in the acquisition and implementation of the OCX system, facilitating its integration into Eversight's operations.
Broadening Diagnostic Horizons: Research & Development Initiatives
Notably, Eversight's Research & Development team will leverage the high-resolution dual-mode OCX system to capture detailed images of both the anterior and posterior segments of the eye. This initiative will facilitate diagnostic imaging for researchers studying retinal diseases, offering insights that could potentially transform the landscape of retinal vision loss treatment.
Dr. Canavesi, a key figure in this collaboration, will present on "Dual-Modality Imaging for Cellular Volumetric Evaluation of Donor Corneal and Retinal Tissues" at the 2024 Eye Bank Association of America (EBAA) annual meeting in Kansas City. The presentation is poised to shed light on the technological advancements achieved through the collaboration between Eversight and LighTopTech, highlighting the anticipated impact on eye and vision research.
